|
|
Line 320: |
Line 320: |
| <a href="#Biomarkers" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> | | <a href="#Biomarkers" data-scroll-to data-scroll-to-offset="50" class="list-group-item list-group-item-action d-flex justify-content-between"> |
| <div> | | <div> |
− | <span>Blood Biomarkers</span> | + | <span>Biomarkers and Liquid Biopsies</span> |
| </div> | | </div> |
| <div> | | <div> |
Line 366: |
Line 366: |
| <div class="col-lg-12"> | | <div class="col-lg-12"> |
| <hr style="height:2px;border:none;color:#333;background-color:#333;" /> | | <hr style="height:2px;border:none;color:#333;background-color:#333;" /> |
− | <h1 id="Biomarkers">Blood Biomarkers</h1> | + | <h1 id="Biomarkers">Biomarkers and Liquid Biopsies</h1> |
− | ..... | + | <p class="lead">Through our dialogue with many health specialists (more info in <a href="https://2018.igem.org/Team:EPFL/Human_Practices"><span style="color:blue">Integrated Human Practices</span></a>), we realized that there was an urgent need for practitioners to be able to evaluate the response to targeted treatments. Assuming, for example, that the treatment has no effect on a certain tumor population, this would be ruled out, saving expenses as well as unnecessary side effects to the patient. In addition, the tumor heterogeneity often generates cases of resistance to targeted therapy (<a href="#Calapre2017"><span style="color:blue">Calapre <i>et al.</i>, 2017</span></a>), via the selection pressure they generate. However, repeated tumor biopsies to study genomic changes are unthinkable in most cases, as these methods are often painful, risky and time-consuming.</p> |
− | <!--<ul class="nav nav-tabs nav-fill flex-column flex-sm-row" id="myTabBiomarkers" role="tablist">
| + | <p class="lead">Recently, several studies have shown that non-invasive <b>liquid biopsy</b> methods are a promising way to detect cancer relapse and monitor tumor burden in cancer (<a href="#Heitzer2017"><span style="color:blue">Heitzer <i>et al.</i>, 2017</span></a>), as these constitute a quick, reliable and easily obtained samples.</p> |
− | <li class="nav-item">
| + | |
− | <a class="nav-link mb-sm-3 active" id="ctDNABiom-tab" data-toggle="tab" href="#ctDNABiom" role="tab" aria-controls="home" aria-selected="true">ctDNA</a>
| + | |
− | </li>
| + | |
− | <li class="nav-item">
| + | |
− | <a class="nav-link mb-sm-3" id="miRNABiom-tab" data-toggle="tab" href="#miRNABiom" role="tab" aria-controls="contact" aria-selected="false">miRNA</a>
| + | |
− | </li>
| + | |
− | </ul>
| + | |
− | | + | |
− | <div class="tab-content" id="ctDNABiom">
| + | |
− | <div class="tab-pane fade show active" id="ctDNACas" role="tabpanel" aria-labelledby="home-tab">
| + | |
− | <p class="lead">ctDNA Cas assay
| + | |
− | <div id="ctDNABiomCard">
| + | |
− | <div class="card" id="trial">
| + | |
− | <a data-toggle="collapse" href="#Biom1">
| + | |
− | <div class="card-header">
| + | |
− | <h3 class="card-link">
| + | |
− | Neoantigen mutated fragments detection for vaccine monitoring
| + | |
− | </h3>
| + | |
− | </div>
| + | |
− | </a>
| + | |
− | <div id="Biom1" class="collapse" data-parent="#ctDNABiomCard">
| + | |
− | <div class="card-body">
| + | |
− | </div>
| + | |
− | </div>
| + | |
− | </div>
| + | |
− | <div class="card" id="trial">
| + | |
− | <a data-toggle="collapse" href="#Biom2">
| + | |
− | <div class="card-header">
| + | |
− | <h3 class="card-link">
| + | |
− | Chromosomal rearrangements as a tool for detecting disease recurrence
| + | |
− | </h3>
| + | |
− | </div>
| + | |
− | </a>
| + | |
− | <div id="Biom2" class="collapse" data-parent="#ctDNABiomCard">
| + | |
− | <div class="card-body">
| + | |
− | </div>
| + | |
− | </div>
| + | |
− | </div>
| + | |
− | </div>
| + | |
− | </p>
| + | |
− | </div>
| + | |
− |
| + | |
− | <div class="tab-pane fade" id="miRNABiom" role="tabpanel" aria-labelledby="contact-tab">
| + | |
− | <p class="lead">miRNA Biom
| + | |
− | <br>
| + | |
− | <p class="lead"><b>miRNAs</b> are instead short (18-24 nt) non-coding RNA molecules which act as post-transcriptional regulators of gene expression. Over the years, miRNAs have been proved to play a critical role in a variety of different diseases and in several aspects of cancer (<a href="#Larrea"><span style="color:blue">Larrea <i>et al.</i>, 2016</span></a>). Moreover miRNAs are remarkably stable in human plasma (<a href="#Mitchell"><span style="color:blue">Mitchell <i>et al.</i>, 2008</span></a>), and recently several miRNAs circulating in the blood have been shown to be dysregulated (either over- or under-expressed) in patients with certain cancers, including melanoma, with respect to healthy subjects (<a href="#Mirzaei"><span style="color:blue">Mirzaei <i>et al.</i>, 2016</span></a>). For these reasons, miRNAs have been proposed as potential prognostic and diagnostic biomarkers for melanoma, which makes them suitable candidates for the follow-up part of our project as well.</p>
| + | |
− | </p>
| + | |
− | </div>
| + | |
− | </div>
| + | |
− | </p>--> | + | |
| <p class="lead"> | | <p class="lead"> |
| <ul class="nav nav-tabs nav-fill flex-column flex-sm-row" id="myTabAmplification" role="tablist"> | | <ul class="nav nav-tabs nav-fill flex-column flex-sm-row" id="myTabAmplification" role="tablist"> |
Line 948: |
Line 899: |
| <li id="Zetsche2017">Zetsche, Bernd, et al. "Multiplex gene editing by CRISPR–Cpf1 using a single crRNA array." <i>Nature biotechnology</i>, 35.1 (2017): 31. </li> | | <li id="Zetsche2017">Zetsche, Bernd, et al. "Multiplex gene editing by CRISPR–Cpf1 using a single crRNA array." <i>Nature biotechnology</i>, 35.1 (2017): 31. </li> |
| <li id="Olsson2015">Olsson, E. et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. <i>EMBO Mol Med</i>, 7, 1034–1047 (2015).</li> | | <li id="Olsson2015">Olsson, E. et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. <i>EMBO Mol Med</i>, 7, 1034–1047 (2015).</li> |
| + | <li id="Calapre2017">Calapre, Leslie, et al. "Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma." <i>Cancer letters</i>, 404 (2017): 62-69.</li> |
| + | <li id="Heitzer2017">Heitzer, Ellen, et al. "The potential of liquid biopsies for the early detection of cancer." <i>NPJ precision oncology</i>, 1.1 (2017): 36.</li> |
| | | |
| <li id="Mitchell">Mitchell, Patrick S., et al. "Circulating microRNAs as stable blood-based markers for cancer detection." <i>Proceedings of the National Academy of Sciences</i>, 105.30 (2008): 10513-10518.</li> | | <li id="Mitchell">Mitchell, Patrick S., et al. "Circulating microRNAs as stable blood-based markers for cancer detection." <i>Proceedings of the National Academy of Sciences</i>, 105.30 (2008): 10513-10518.</li> |